Event Information

Time：October 8, 2014 (Wednesday) 04:30-06:30 p.m.

Place：TRPMA Conference Room
（1F, No. 465-1, Sec. 6, Zhongxiao E. Rd., Nangang Dist., Taipei City 11557, Taiwan）

The TRPMA invited Prof Yang Chih-Hsin, Chief Director of the Cancer Administration and Coordination Center of the NTUH, to give a special speech on October 8. Prof Yang is a leading authority on lung cancer clinical researches with considerable experiences in multi-center clinical trial projects and extensive research results. He was frequently invited to give speeches in international academic seminars and is keen to cultivate future talents in the field of cancer clinical trials.

Prof Yang began the speech by reviewing the history of oncology and clinical trials in Taiwan, including the establishment of the Taiwan Cooperative Oncology Group (TCOG) in 1989 with the assistance from Dr Paul Carbone. The TCOG marked the beginning of the cancer clinical researches in Taiwan.

Prof Yang gave a detailed introduction of the cancer drugs in his past clinical researches. For example, the development process of a lung cancer drug for patients with EGFR mutation and the mechanism of action and the development of the 2nd generation of “Afatinib”. Prof Yang also analysed the current progresses of lung cancer drug development in other countries.

Prof Yang pointed out the potentials and weaknesses of the clinical trials in Taiwan. The academic in Taiwan has a remarkable ability in drug synthesis. However, the academic need to strengthen their communication with clinical trial organizations so as to expedite new drug researches. Ms Hsu Ming-Chu, President of TaiGen, and Mr Yeh Chang-Ching, General Manager of PharmaEgine, both made comments. They mentioned that doctors in Taiwan are particularly concerned about Phase I clinical trials, partly because of the legal liabilities; furthermore, the assessment of clinical trial applications is lengthy and time consuming. If the regulations can be revised and the quality and number of reviewers can be improved, it certain will contribute to the development of clinical trials in Taiwan.

The TRPMA invited Prof Yang Chih-Hsin, Chief Director of the Cancer Administration and Coordination Center of the NTUH, to give a special speech on the experiences and trend of clinical researches on cancer drugs in Taiwan.